Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Koji Sasaki,Koichi Takahashi,Farhad Ravandi,Patrice Nasnas,Meagan Rostykus,Christopher Loiselle,Corabelle Encarnacion,Jovitta Jacob,Nicholas J Short,Nitin Jain,Monica Kwari,Rebecca Garris,Hagop M Kantarjian,Tapan M Kadia,Richard E Champlin,Xuelin Huang,Rita Khouri,Partow Kebriaei,Guillermo Garcia‐Manero ,Michael Rytting ,Zeev Estrov ,Marina Konopleva ,Jorge E Cortés

doi:10.1182/blood-2019-129018

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Koji Sasaki, Koichi Takahashi + Show 21 more

Open Access

https://doi.org/10.1182/blood-2019-129018

Copy DOI

Journal: Blood	Publication Date: Nov 13, 2019
Citations: 12

Affiliation: The University of Texas MD Anderson Cancer Center

#Research Funding #Inotuzumab Ozogamicin + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Full Text